ARTV

Conviction 56HealthcareScan · Mon, Aug 10, 2026

Three outside down

ARTV$11.20-0.62%

ResistanceSupportVol 14Insider buyInsider sell

Vol MA14 391.55K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Artiva Biotherapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.artivabio.com ↗

Price11.20

Change-0.62%

Gap-0.35%

Rel volume1.34×

Avg volume403.54K

Avg $ vol4.16M

SMA 2010.31

SMA 509.35

SMA 2006.70

Price vs 50+19.72%

Price vs 200+67.18%

MA stackbullish

50/200 cross—

Supertrendup · 9.08

RSI (14)60

MACD hist0.10

MACD cross—

Stoch %K / %D69 / 76

ADX (14)26

+DI / −DI21 / 12

RSI divergence—

MACD divergence—

ATR %+7.73%

ADR %8.81%

52w high13.39

52w low2.28

From 52w high-16.36%

Above 52w low+391.23%

New 52w highNo

SqueezeOff

Bollinger width28.18%

%B0.81

Donchian pos74.02%

Donchian high12.06

Donchian low8.75

AVWAP (52w high)9.68

vs AVWAP high+15.74%

AVWAP (52w low)6.28

vs AVWAP low+78.46%

OBV trendUp

Chaikin MF (20)0.19

Today vs 20d1.34×

Avg vol (14d)391.55K

Avg vol (20d)403.54K

Avg $ vol (20d)4.16M

Market cap547.57M

RS 3m (vs SPY)-15.68%

RS 6m (vs SPY)+177.10%

RS line new highNo

Trend template7/8

Technical rank90.3

1 week+4.09%

1 month+16.18%

3 months+2.85%

6 months+177.92%

1 year+324.24%

YTD+164.78%

P/E-6.53

P/B1.58

P/S16.63

P/FCF-6.90

EPS-3.43

Div yield—

ROE-24.13%

ROA-22.75%

Debt/Eq—

Current24.16

EV/EBITDA-2.82

Gross margin—

Net margin-254.73%

Rev growth—

EPS growth-28.29%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value246.12M

Revenue26.66M

Net income-25M

Gross profit—

Free cash flow-79.34M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out24.72M

Employees106

ListedFri, Jul 19, 2024

Free float5.69M

Float %23.2%

Short interest1.72M

Days to cover3.8d

Short volume71.4%

Squeeze score84 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.63 vs −$0.64

Last surprise+1.6% beat

Setup gradeC

Conviction56 / 100

Pattern quality—

Tech rank90.3 / 100

Group rank86 / 100 · Leading

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmThree outside down

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ARTV

All disclosures →

No recent disclosed trades by Congress in ARTV. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ARTV · 10 buys

Insider	Side	Shares	Value	Traded	Filed
RA CAPITAL MANAGEMENT, L.P. Director · Common Stock · 2026-07-24	Buy	41.32K	$413K	2026-07-24	2026-07-28
RA CAPITAL MANAGEMENT, L.P. Director · Common Stock · 2026-06-26	Buy	1.88K	$17K	2026-06-26	2026-06-29
RA CAPITAL MANAGEMENT, L.P. Director · Common Stock · 2026-06-25	Buy	31K	$275K	2026-06-25	2026-06-29
RA CAPITAL MANAGEMENT, L.P. Director · Common Stock · 2026-06-16	Buy	124.89K	$1.1M	2026-06-16	2026-06-16
RA CAPITAL MANAGEMENT, L.P. Director · Common Stock · 2026-06-15	Buy	15.41K	$139K	2026-06-15	2026-06-16
RA CAPITAL MANAGEMENT, L.P. Director · Common Stock · 2026-06-12	Buy	391.02K	$3.4M	2026-06-12	2026-06-16
GC Cell Corp 10% owner · Common Stock · 2026-05-11	Buy	1.09M	$12M	2026-05-11	2026-05-28
GC Corp. 10% owner · Common Stock · 2026-05-11	Buy	347.22K	$4.0M	2026-05-11	2026-05-28
GC Cell Corp 10% owner · Common Stock · 2026-05-11	Buy	347.22K	$4.0M	2026-05-11	2026-05-28
GC Corp. 10% owner · Common Stock · 2026-05-11	Buy	1.09M	$12M	2026-05-11	2026-05-28

SEC filings

EDGAR filings in ARTV · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.